
Ep. 340 Understanding Intermediate-Risk Bladder Cancer with Dr. Wesley Yip
By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, treat in the office, or start intravesical therapy. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Wesley Yip, urologic oncologist at City of Hope, to rethink what she calls the forgotten stepchild of bladder cancer: intermediate-risk non-muscle invasive bladder cancer (NMIBC). Dr. Yip explains why he sees the category as a catch-all rather than a single biological entity, by his estimate covering 50 to 60 percent of NMIBC, why he now relies on the International Bladder Cancer Group (IBCG) definition, and why tumor grade comes first, ahead of multiplicity, size, and recurrence timing.
Publisher
BackTable Urology
Published
November 3, 2026
Duration
44 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
BackTable Inc.
BackTable Urology
@backtableurology
#understandingintermediate #riskbladdercancer #wesleyyip #medicine
